Basel Medical Group Ltd Ordinary Shares (BMGL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Basel Medical Group Ltd Ordinary Shares stock (BMGL) is currently trading at $0.64. Basel Medical Group Ltd Ordinary Shares PS ratio (Price-to-Sales) is 1.23. WallStSmart rates BMGL as Sell.
- BMGL PE ratio analysis and historical PE chart
- BMGL PS ratio (Price-to-Sales) history and trend
- BMGL intrinsic value — DCF, Graham Number, EPV models
- BMGL stock price prediction 2025 2026 2027 2028 2029 2030
- BMGL fair value vs current price
- BMGL insider transactions and insider buying
- Is BMGL undervalued or overvalued?
- Basel Medical Group Ltd Ordinary Shares financial analysis — revenue, earnings, cash flow
- BMGL Piotroski F-Score and Altman Z-Score
- BMGL analyst price target and Smart Rating
Basel Medical Group
📊 No data available
Try selecting a different time range
Smart Analysis
Basel Medical Group Ltd Ordinary Shares (BMGL) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Basel Medical Group Ltd Ordinary Shares (BMGL) Key Strengths (2)
Paying $1.23 for every $1 of annual revenue
Strong revenue growth at 27.30% annually
Supporting Valuation Data
Basel Medical Group Ltd Ordinary Shares (BMGL) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very low institutional interest at 0.80%
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 3.7x book value
Basel Medical Group Ltd Ordinary Shares (BMGL) Detailed Analysis Report
Overall Assessment
This company scores 27/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 8.0/10) while 6 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Revenue Growth. Valuation metrics including Price/Sales (1.23) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 27.30%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Book (3.69) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -163.60%, Operating Margin at -24.90%, Profit Margin at -93.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -163.60% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 27.30% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BMGL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BMGL's Price-to-Sales ratio of 1.23x trades at a 24% premium to its historical average of 0.99x (86th percentile). The current valuation is 0% below its historical high of 1.23x set in Mar 2026, and 34% above its historical low of 0.92x in Mar 2026. Over the past 12 months, the PS ratio has expanded from ~1.0x, reflecting growing market expectations outpacing revenue growth.
Compare BMGL with Competitors
Top MEDICAL CARE FACILITIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Basel Medical Group Ltd Ordinary Shares (BMGL) · HEALTHCARE › MEDICAL CARE FACILITIES
The Big Picture
Basel Medical Group Ltd Ordinary Shares is a strong growth company balancing expansion with improving profitability. Revenue reached 11M with 27% growth year-over-year. The company is currently unprofitable, posting a -93.7% profit margin.
Key Findings
Revenue growing at 27% YoY, reaching 11M. This pace significantly outperforms most MEDICAL CARE FACILITIES peers.
The company is unprofitable with a -93.7% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -4M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Basel Medical Group Ltd Ordinary Shares maintain 27%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor MEDICAL CARE FACILITIES industry trends, competitive moves, and regulatory changes that could impact Basel Medical Group Ltd Ordinary Shares.
Bottom Line
Basel Medical Group Ltd Ordinary Shares offers an attractive blend of growth (27% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Basel Medical Group Ltd Ordinary Shares(BMGL)
NASDAQ
HEALTHCARE
MEDICAL CARE FACILITIES
USA
Basel Medical Group Ltd provides healthcare services. The company is headquartered in Singapore.